Connect with us


New Treatment for Pediatric Ulcerative Colitis Submitted for FDA Orphan Drug Classification



A New, Non-Corrosive, Non-Irritating Treatment for Pediatric Ulcerative Colitis Has Been Submitted for FDA‘s Orphan Drug Classification

Financial Press Commentary

(FinancialPress) — The US Federal Drug Administration (FDA) has received an orphan drug designation request from Vitality Biopharma Inc. (OTCQB: VBIO)—a cannabinoid prodrug pharma corporation in the process of developing its flagship asset VITA-100, targeting the treatment of pediatric ulcerative colitis.

A positive response from the FDA’s Office of Orphan Products Development stands to benefit the company as it continues to develop the treatment.

The drug could potentially serve to alleviate the pediatric condition – which holds a rare disease classification itself.

VITA-100 holds the particular distinction of being based on Vitality’s proprietary “cannabosides” technology—a delivery system aimed to deliver therapeutic-grade cannabinoids (THC and CBD) directly to the targeted area in the gastro-intestinal tract without the composite entering the bloodstream. The benefit of this delivery method is the avoidance of all psychoactive effects traditionally associated with it.

“In young children, ulcerative colitis can often be hyperactive and difficult to control using existing FDA-approved medications,” said Robert Brooke, CEO and Co-Founder of the company.

“Given the mounting clinical data documenting use of cannabinoids for treatment of gastrointestinal disorders, we are very excited about the potential of VITA-100 and our cannabosides platform to provide a meaningful impact for these patients, helping them to stabilize their disease and avoid debilitating surgeries,” he added. 

The cannabosides technology has already been tested and demonstrated as effective by the company—particularly in preclinical models of colitis.

The non-intoxicant formulation also helped reduce the side effects that often come with similar treatments such as weight loss, damage to the colon and overall improved GI health when compared to placebos.

The restricted delivery-drug, enabled by the company’s know-how in enzymatic glycosylation, is geared up to be available as an oral pharmaceutical.

Formerly a stevia-focused company, Vitality is one of the few companies operating in the cannabinoid pharmaceutical sector.

It found its niche in obtaining its own intellectual properties in the aforementioned delivery system.

Their inaugural discovery in the field came as it attempted to make stevia taste better. They found a much better – and more exploitable – result in lieu.

Therapeutic synthetic THC, AKA dronabinol, has been an instrumental factor in giving companies such as Vitality a head start over the rest of the medicinal cannabis sector, as the FDA‘s 2016 approval has allowed them to delve deeper into the medical uses and benefits of the cannabinoid.

The legal THC sector has been making waves ever since the approval, with companies such as Valeant Pharmaceuticals, Inc. (NYSE: VRX) (TSX: VRX) and INSYS Therapeutics, Inc. (NASDAQ: INSY) releasing their products Marinol and Syndros respectively – both of which use the cannabis derivate as the active ingredient. GW Pharmaceuticals plc (NASDAQ: GWPH) is also expected to have its Sativex (naxibimol) product approved soon.

Vitality‘s submission brings it one step closer to tapping into the massive medicinal cannabinoid market, putting it neck and neck with the giants of the sector while having only a fraction of, for example, GW‘s $3.723 billion market cap.


Valeant Pharmaceuticals, Inc. (NYSE: VRX) (TSX: VRX)

Valeant operates as a pharmaceutical and medical device company worldwide. Among its many products, the company offers Uceris to get ulcerative colitis under control; and Zegerid to treat certain stomach and esophagus problems; Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; and Latanoprost medicines to treat a type of glaucoma. The company was founded in 1983 and is headquartered in Laval, Canada.

INSYS Therapeutics, Inc. (NASDAQ: INSY)

Insys Therapeutics, Inc., is a specialty pharmaceutical company, which develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

GW Pharmaceuticals plc (NASDAQ: GWPH)

GW is a biopharmaceutical company, engaging in discovering, developing, and commercializing cannabinoid prescription medicines derived from the Cannabis plant. GW markets Sativex, for the treatment of spasticity due to multiple sclerosis, which is also in Phase II trials for neuropathic pain. Their product pipeline includes Epidiolex, which is in Phase III clinical development to treat dravet syndrome, lennox-gastaut syndrome, tuberous sclerosis complex, and infantile spasms. GW Pharmaceuticals plc was founded in 1998 and is based in the UK.

About Vitality Biopharma (OTCQB: VBIO)

Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: Follow us on Facebook, Twitter and LinkedIn


This content is the view of the author and should not be considered a solicitation to buy or sell stock. Always consult an investment advisor before making any trading decisions. A fee has been paid for the creation and distribution of this content. is operated by Stock Social Inc. and owners of which may directly or indirectly own securities in the profiled companies in this article. This presents a potential conflict of interest by the author(s) and information should be considered biased. We do not make claims to any accuracy of the statements within. Always do your own due diligence and consult a registered advisor when making any trading decision. does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers. Information presented by may contain “forward-looking statements ” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects, ” “will, ” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


MassRoots Expands Product Portfolio with New Partner and Acquisition of COWA Science



With predictions that the legal cannabis market will experience non-linear growth in the coming years underscored by ongoing legalization of marijuana worldwide, companies big and small are hustling to build their footprints to capture share in a market that  Grand View Research forecasts will reach $146.4 billion by the end of 2025 (from $7.1 billion in 2016).  Whether companies are touching the once-taboo plant or operating in an ancillary segment, there is no shortfall of growth opportunities as part of an abolishment of eight decades of cannabis prohibition.

For its part, MassRoots (OTCQB: MSRT), a technology and rewards platform at its core, is branching out into different verticals.  Since the start of 2019, the company has penned two substantive agreements that have expanded MassRoots’ portfolio of products and services.

In mid-January, the Los Angeles-based company partnered with We are Kured, a subsidiary of New Age Brands (CSE: NF)(OTC:NWGFF), to serve as the leading online retailer of We are Kured’s best-selling CBD Pen.   The handheld vaporizer pen dispenses cannabidiol, or CBD, a THC-free constituent of hemp and cannabis trumpeted for its therapeutic benefits relating to alleviating inflammation, pain, anxiety, seizures and a host of other symptoms from a variety of maladies without unpleasant side effects or psychotropic buzz often associated with marijuana. 

The pen represents a new revenue stream for MassRoots as the first CBD product to be sold directly through the company’s online platform and social media pages.  MassRoots has more than one million social media followers, in excess of 750,000 email subscribers and hundreds of thousands of unique monthly visitors on its website and application to whom it can market the product.

This month, MassRoots entered a definitive agreement to acquire supply-chain as a service company COWA Science Corp. in an all-stock deal valued at approximately $5.78 million.  The buyout terms are dependent upon COWA Science meeting annual revenue milestones of $2.5 million and $7.5 million, as well as other customary closing conditions.  In short, the terms specify that COWA shareholders are entitled to additional shares if the sales milestones are hit within three years of the effectiveness of the merger.

For 2018, unaudited financials show COWA Science generated revenue of approximately $1.5 million by providing a variety of products and services to its list of about 50 cannabis- and hemp-focused clients.  Upon completion of the transaction, COWA will become a wholly-owned subsidiary of MassRoots.

MassRoots expects the acquisition to be immediately accretive while diversifying its business.  Management expects to build upon the existing COWA Science business to offer a complete cannabis-centric suite covering the full supply chain, including advertising, consumer packaging, process and product development, growing supplements and nutrients, HVAC and more.  On the whole, the new, bigger MassRoots intends to provide a broad mix of offerings to hundreds of licensed cannabis business in key markets across the country.

“Going forward, MassRoots is confident that the addition of COWA Science will increase overall revenues and expand our market presence, with the goal of generating positive cash-flows from operations,” commented MassRoots CEO Isaac Dietrich in the press release on the acquisition.  Dietrich added that the decision to bring COWA Science under his company’s umbrella came after several years of following their business and growth trajectory.

Online Media Group, Inc. is not registered with any financial or securities regulatory authority and holds no investment licenses and does not provide, nor claims to provide, investment advice. We are a publisher of original and third-party news and information. This article is sponsored content and is neither an offer nor recommendation to buy, sell or hold any security. The views expressed are our own and not intended to be the basis for any investment decision. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader’s attention to the fact that Online Media Group, Inc. received $1,333 in compensation from a third-party for content creation, advertising and distribution services related to this material.

Continue Reading


Nationwide US cannabis legalization lawsuit movement scores an L



(FinancialPress) — The first legal battle held by the lawsuit levvied against the federal government, launched by cannabis legalization advocates, finds the plaintiffs on the losing side.
Judge Alvin Hellerstein, who officiates for the U.S. District Court in the Southern District of New York, ruled that the plantiffs “failed to exhaust all administrative remedies“ to settle their request, and therefore granted the motion to dismiss filed by the U.S. Justice Department.
The suit argues for the unconstitutionality of the 1970 Controlled Substances Act, and requested that marijuana be reclassified from the schedule of controlled narcotics.
Had the suit been successful, marijuana would have been immediately legalized country-wide.

The ruling will be appealed by the plaintiffs – a group that includes a young epileptic girl and former NFL players.

Hellerstein‘s ruling read as follows:

“Although plaintiffs couch their claim in constitutional language, they seek the same relief as would be available in an administrative forum – a change in marijuana’s scheduling classification – based on the same factors that guide the (Drug Enforcement Administration’s) reclassification determination.”

The judge emphasized the fact that the ruling was an administrative measure, and should not be taken as support towards the notion of that marijuana should remain classified a Schedule I drug:

“This decision should not be understood as a factual finding that marijuana lacks any medical use … the authority to make that determination is vested in the administrative process,” he wrote.

He also denied the plaintiffs‘ claim of that using marijuana is a fundamental right of theirs.

“No such fundamental right exists,” he wrote.

“Every court to consider the specific, carefully framed right at issue here has held that there is no substantive due process right to use medical marijuana.”

Continue Reading


Alibaba bets big on Olympics for household recognition



(FinancialPress) — The biggest e-commerce portal in China is making a strong investment as an Olympic sponsor for the Pyeongchang Olympic games. The imposing pavilion the company put up at the event is in line with the ones erected by giants Coca-Cola, McDonald‘s and Samsung.

With this, Alibaba (BABA) likely hopes that some of the 3 other giants‘ global recognition rubs off on it.

The Jack Ma-founded company made waves with its 2014 New York Stock Exchange IPO – the largest recorded in history. The eccentric frontman is a regular at major international events, and just last year was part of a photo op with US President Donald Trump.

However, despite its massive success in Asia, its  “brand awareness outside China is not commensurate with its size,” according to National University of Singapore marketing professor Junhong Chu. Alibaba‘s market value is larger than Walmart‘s, and the company looks to change that with the Olympic sponsorship.

The requirements of the contract are extensive – minimum commitment of 4 years, and hundreds of millions in investment. While the exact numbers are not required to be made public, a report states that BABA‘s estimated investment will border $800 milion for the duration of the deal, which ends in 2028. This puts the company shoulder-and-shoulder with name giants such as Toyota, GE and Visa.

Alibaba steps in at a critical time – as longtime main sponsor McDonald‘s announced it will end its deal with the Olympics 3 years early. Not only does the new partnership bridge that financial hole, but a spokesperson for the Asian giant also stated that it comes “at a very critical time,” and that it will use its technology to help make the Olympics “more efficient, secure and engaging,”

Continue Reading

Most Popular